Antihypertensive impacts and safety of aurogra have been developed in pediatric patients aged 6 to 16 years [seeDosage and Administration (2.1) as well as Clinical Studies (14.1)] No pertinent differences between the unfavorable response profile for pediatric people and also adult patients were recognized.